Boston Scientific Corp. vs. InfuSystem Holdings, Inc.
Boston Scientific Corp. (BSX) comes out ahead, leading on 7 of 9 compared factors.
Size & Scale
| BSX | INFU | |
|---|---|---|
| Market Cap | $71.45 billion | $248.77 million |
| Revenue (TTM) | $21.00 billion | $143.34 million |
| Net Income (TTM) | $3.67 billion | $8.54 million |
BSX leads on 3 of 3 size & scale factors.
Valuation
| BSX | INFU | |
|---|---|---|
| P/E Ratio | 19.96 | 31.22 |
| Price / Book | 2.84 | 4.21 |
| Price / Sales | 3.40 | 1.74 |
BSX leads on 2 of 3 valuation factors.
Profitability
| BSX | INFU | |
|---|---|---|
| Net Margin | 17.47% | 5.96% |
| Return on Equity | 14.58% | 14.44% |
BSX leads on 2 of 2 profitability factors.
Risk & Sentiment
| BSX | INFU | |
|---|---|---|
| Short Interest | 0.70% | 0.02% |
INFU leads on 1 of 1 risk & sentiment factors.
Dig deeper: BSX overview, BSX financials, INFU overview, INFU financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.
